Miranda Jayne Toledano Purchases 11,000 Shares of Entera Bio (NASDAQ:ENTX) Stock

Entera Bio Ltd. (NASDAQ:ENTX) CEO Miranda Jayne Toledano purchased 11,000 shares of the stock in a transaction that occurred on Monday, December 29th. The shares were purchased at an average price of $1.81 per share, with a total value of $19,910.00. Following the completion of the acquisition, the chief executive officer directly owned 426,575 shares in the company, valued at $772,100.75. The trade was a 2.65% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Entera Bio Stock Up 4.7%

Shares of Entera Bio stock opened at $1.80 on Tuesday. The company’s fifty day simple moving average is $2.38 and its two-hundred day simple moving average is $2.11. Entera Bio Ltd. has a 12-month low of $1.50 and a 12-month high of $3.22. The firm has a market cap of $82.55 million, a PE ratio of -7.20 and a beta of 1.71.

Entera Bio (NASDAQ:ENTX) last posted its earnings results on Friday, November 14th. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.02. Entera Bio had a negative net margin of 4,525.11% and a negative return on equity of 67.56%. As a group, sell-side analysts expect that Entera Bio Ltd. will post -0.28 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Parkman Healthcare Partners LLC grew its holdings in shares of Entera Bio by 6.3% during the first quarter. Parkman Healthcare Partners LLC now owns 439,632 shares of the company’s stock valued at $747,000 after buying an additional 25,900 shares during the last quarter. Bessemer Group Inc. bought a new position in Entera Bio in the 2nd quarter valued at approximately $268,000. Citadel Advisors LLC boosted its stake in Entera Bio by 243.0% during the 3rd quarter. Citadel Advisors LLC now owns 39,978 shares of the company’s stock valued at $77,000 after purchasing an additional 28,322 shares during the last quarter. Finally, HighTower Advisors LLC increased its holdings in shares of Entera Bio by 53.3% in the 1st quarter. HighTower Advisors LLC now owns 18,140 shares of the company’s stock worth $31,000 after purchasing an additional 6,310 shares in the last quarter. Hedge funds and other institutional investors own 14.11% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on ENTX shares. Wall Street Zen raised Entera Bio to a “sell” rating in a research note on Saturday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Entera Bio in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Entera Bio has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Entera Bio Company Profile

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.